Cargando…
Pharmaceutical Sponsorship Bias Influences Thrombolytic Literature in Acute Ischemic Stroke
BACKGROUND: The efficacy of thrombolytic therapy for acute ischemic stroke remains controversial in emergency medicine and has not been fully endorsed by either the American College of Emergency Physicians or the American Academy of emergency medicine. A growing recognition exists of the influence o...
Autor principal: | Radecki, Ryan Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Department of Emergency Medicine, University of California, Irvine
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236136/ https://www.ncbi.nlm.nih.gov/pubmed/22224134 http://dx.doi.org/10.5811/westjem.2011.5.2166 |
Ejemplares similares
-
Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship
por: McPartland, John M.
Publicado: (2009) -
Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
por: Stemer, Andrew, et al.
Publicado: (2010) -
Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
por: Alhadid, Kenda, et al.
Publicado: (2023) -
Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis
por: Misemer, Benjamin S., et al.
Publicado: (2016) -
Thrombolytic or endovascular therapy for acute ischemic stroke: Time is brain
por: Mijajlovic, Milija D.
Publicado: (2014)